Partner Intake & Study Scoping
Subtilitas programs are scoped collaboratively with pharma and biotechnology partners to align biomarker collection, analytics, and development objectives.
Core Study Inputs
Indication & mechanism
Disease area, target pathway, and hypothesis
Program stage
Discovery, preclinical, Phase 1–3, or post‑approval
Sampling design
Lesional vs non‑lesional, longitudinal cadence
Sample size
Cohorts, controls, enrichment strategy
Endpoints
Exploratory, pharmacodynamic, stratification, predictive
Analytics and Outputs
Transcriptomic signatures and pathway activation scores
Responder / non‑responder classification models
Biomarker panels for development decision support
Evidence packages for internal governance and external stakeholders
Next Steps
Partners typically begin with a scoping call to align objectives, timelines, and feasibility.